Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Rhea-AI Summary

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will feature on The RedChip Money Report® on Bloomberg TV on April 22, 2023, at 7 p.m. ET. The interview includes insights from CEO Laxminarayan Bhat regarding the Company’s Phase 3 trial for schizophrenia and promising safety and efficacy results from the Phase 2 study. Reviva’s focus is on developing next-generation therapeutics to address unmet medical needs, with ongoing research on drug candidates like brilaroxazine (RP5063) and RP1208. Reviva holds composition of matter patents for both candidates in the U.S. and Europe. The RedChip Money Report® aims to provide investors with valuable information on small-cap investing and features various financial insights.

Positive

• CEO Laxminarayan Bhat discussed positive safety and efficacy data from the Phase 2 trial for schizophrenia, which may bolster investor confidence.
• Reviva's development pipeline includes two promising drug candidates, indicating potential for future growth.

Negative

• None.

ORLANDO, FL / ACCESSWIRE / April 19, 2023 / RedChip Companies will air a new interview with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) on The RedChip Money Report® on Bloomberg TV, this Saturday, April 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Interview highlights:

In the exclusive RedChip Money Report interview, Reviva's Founder and CEO Laxminarayan Bhat discusses the Company's Phase 3 trial for schizophrenia, positive safety and efficacy data from the Phase 2 study, the potential applications in other indications, and much more.

Access this interview in its entirety at https://www.rvphinfo.com/interview_access

About The RedChip Money Report®

The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Reviva Pharmaceuticals Holdings, Inc.

Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and R1208 in the United States, Europe, and several other countries. For more information, please visit the Reviva website and Corporate Presentation.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
RVPH@redchip.com

SOURCE: RedChip

View source version on accesswire.com:
https://www.accesswire.com/750110/Reviva-Pharmaceuticals-Holdings-Inc-Interview-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR

FAQ

What is Reviva Pharmaceuticals' interview about on Bloomberg TV?

The interview on Bloomberg TV will discuss Reviva's Phase 3 trial for schizophrenia and its Phase 2 study results.

When will Reviva Pharmaceuticals' interview air on Bloomberg TV?

The interview will air on April 22, 2023, at 7 p.m. ET.

What is the significance of Reviva's Phase 2 trial results?

The Phase 2 trial results show promising safety and efficacy data, which could impact future drug development and investor interest.

What drug candidates is Reviva Pharmaceuticals developing?

Reviva is developing brilaroxazine (RP5063) and RP1208, both of which have received composition of matter patents.

How can investors access the interview with Reviva Pharmaceuticals?

Investors can access the full interview through the provided link in the press release.